

Innovative Medicines Initiative launches IMI 2 – Call 7

The **Innovative Medicines Initiative (IMI)** has launched a **new Call for proposals**, giving researchers from diverse sectors the opportunity to participate in **ambitious public-private partnerships** that will pave the way for the development of the **medicines of the future**.

IMI encourages small and medium-sized enterprises (SMEs), mid-sized companies, patients' organisations, regulatory authorities, academic teams, industry, hospitals and other organisations to form consortia and apply to participate in the new IMI projects.

IMI 2 – Call 7 includes the following topics:

- Validation of **translational imaging** methods in **drug safety assessment** (TRISTAN)
- Identification of **druggable targets** modulating misfolded proteins in **Alzheimer's** and **Parkinson's** diseases
- Pathological **neuron-glia** interactions in **neuropathic pain**
- Dry age-related **macular degeneration**: development of novel clinical endpoints for **clinical trials** with a regulatory and patient access intention
- A comprehensive '**paediatric preclinical POC platform**' to enable clinical molecule development for **children with cancer**

Topics under the **Big Data for Better Outcomes** programme:

- **Coordination and Support Actions (CSA)** for the Big Data for Better Outcomes programme
- Increase **access** and use of **high quality data** to improve **clinical outcomes** in **heart failure (HF)**, **atrial fibrillation (AF)**, and **acute coronary syndrome (ACS)** patients

Find out more

The **full texts** of the topics and details of **how to apply** can be found on the IMI website: bit.ly/IMI2Call7

IMI will also hold **webinars** on the topics in **January 2016**. Visit the IMI events page for details & to register: bit.ly/1IS4lic

Deadline for submitting short proposals

- **17 March 2016**

Find project partners

IMI's **Partner Search Tool** - www.imi.europa.eu/content/partner-search - allows people interested in applying for IMI funding to search for potential project partners. It has been updated with the IMI 2 – Call 7 topics.

Why apply?

- Obtain **research funding**
- Take part in **scientifically excellent, patient-centric** research – IMI's research agenda for 2014-2024 focuses on getting the **right prevention and treatment** to the **right patient** at the **right time**
- Join unique consortia involving **top teams** from industry, academia, SMEs, regulators, and others
- Benefit from the **expertise, databases, and infrastructures** of consortium partners
- Boost the **visibility and status** of your organisation in Europe and globally and gain **access to new markets**

What's new in IMI 2?

- **Simplified rules** (in line with Horizon 2020)
- **Simpler funding rates** plus more types of organisation now eligible for funding
- Option for **other industrial / large-scale partners** to contribute

Spread the word

IMI's Calls for proposals offer researchers across Europe a **unique opportunity to participate in ground-breaking projects** that aim to deliver **tangible benefits for patients**.

Spread the word by **forwarding this flyer** to your contacts and networks.

You can also use the material at: www.imi.europa.eu/content/documents

About the Innovative Medicines Initiative

The Innovative Medicines Initiative (IMI) is working to **improve health** by speeding up the development of, and patient access to, **the next generation of medicines**, particularly in areas where there is an **unmet medical or social need**. It does this by **facilitating collaboration** between the key players involved in healthcare research, including universities, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators.

IMI is a **partnership** between **the European Union** and the **European pharmaceutical industry**, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA). IMI has a budget of **€3.276 billion** for the period 2014-2024. Half of this comes from the EU. The other half comes from large companies, mostly from the pharmaceutical sector; these do not receive any EU funding, but contribute to the projects 'in kind', for example by donating their researchers' time or providing access to research facilities or resources.

IMI was launched in 2008 and currently has over 60 ongoing projects, with more in the pipeline. Some focus on **specific health issues** such as neurological conditions (Alzheimer's disease, schizophrenia, depression, chronic pain, and autism), diabetes, lung disease, oncology, inflammation & infection, tuberculosis, and obesity.

Others focus on **broader challenges in drug development** like drug and vaccine safety, knowledge management, the sustainability of chemical drug production, the use of stem cells for drug discovery, drug behaviour in the body, the creation of a European platform to discover novel medicines, and antimicrobial resistance. In addition to research projects, IMI supports **education and training** projects.

Stay in touch

- Visit the IMI website: www.imi.europa.eu
- Sign up to the IMI Newsletter: bit.ly/IMInewsletter
- Follow us on Twitter: [@IMI_JU](https://twitter.com/IMI_JU)
- Join the Innovative Medicines Initiative group on LinkedIn: bit.ly/LinkedInIMI
- E-mail us: infodesk@imi.europa.eu
- Your national IMI contact: bit.ly/IMISRG